Benzodiazepines and Related Sedatives.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 34823725.
- Also identified by DOI 10.1016/j.mcna.2021.08.012.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Benzodiazepine and related sedative use has been increasing. There has been a growing number of unregulated novel psychoactive substances, including designer benzodiazepines. Benzodiazepines have neurobiological and pharmacologic properties that result in a high potential for misuse and physical dependence. Options for discontinuing long-term benzodiazepine use include an outpatient benzodiazepine taper or inpatient withdrawal management at a hospital or detoxification facility. The quality of evidence on medications for benzodiazepine discontinuation is overall low, whereas cognitive behavioral therapy has shown the most benefit in terms of behavioral treatments. Benzodiazepines may also have significant adverse effects, increasing the risk of overdose and death.
Medical subject headings
- Benzodiazepines
- Drug Tapering
- Hypnotics and Sedatives
- Substance Withdrawal Syndrome
- Substance-Related Disorders